Nathaniel Watson, MD
Neurology · Seattle, WANPI 1528144342
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $433,640 of the $486,071 with a category attached, or 89.2%. 8 manufacturers reported payments, led by Ensodata, Inc. at 58.3% of the total. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $2809.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ensodata, Inc.$283K
- Idorsia Pharmaceuticals US Inc$77K
- Jazz Pharmaceuticals Inc.$59K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Harmony Biosciences LLC$16K
- Eisai Inc.$10K
- plus $10K from 2 others
Across 3 payments — averaging $4175.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Idorsia Pharmaceuticals US Inc$10K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
Across 1 payment — averaging $7200.20 each. An ownership or investment interest held by the physician or an immediate family member.
- Ensodata, Inc.$7K
What the payments were for
- Consulting fees$433,64089%
- Speaking & faculty fees$30,5536%
- Travel & lodging$14,9743%
- Food & beverage$4,0581%
- Education$1,0960%
- Other$1,7500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ensodata, Inc. | 18 | $283,164 |
| Idorsia Pharmaceuticals US Inc | 38 | $76,575 |
| Jazz Pharmaceuticals Inc. | 58 | $58,693 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $31,485 |
| Harmony Biosciences LLC | 18 | $15,576 |
| Eisai Inc. | 12 | $10,202 |
| 3b Medical, Inc. | 6 | $9,000 |
| Biogen | 1 | $1,375 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$486,071 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 26 | $2,585 |
| Modafinil | 25 | $1,657 |
Paid to pharmacies, not to this prescriber.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
- Leo WangSeattle$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.